WaveData Ltd

Charles Joynson, WaveData MD, shares his thoughts on this year’s Pharmacy Show. This year’s Pharmacy Show was as interesting as ever, with a huge number of stands and an amazing variety of products on show. However, in the 15 or so years that we’ve been attending this event we’ve noticed its nature has changed substantially from a focus on supply chain and prescription medicine to a strong over-the-counter emphasis. In the early days you could expect to see major distributors such as AAH, Sigma, Lexon or Ethigen, and generic manufacturers like Teva and Actavis, now however you can expect to see a smattering of Major branded manufacturers exhibiting their vaccines, but almost everything else relates to over-the-counter or GSL products such as vitamins, supplements and IBS treatments. There has always been a focus on machinery and on software which remains, but the stands for these organisations have got bigger over the last 15 years. The reason for these changes is almost certainly Pharmacy profitability. This is very much tied down to the way prescription medicines are reimbursed: branded through the VPAG scheme and generics through the Drug Tariff and Category M. Neither of these schemes is very profitable for pharmacies or manufacturers, which means that the money simply isn’t flowing from the DHSC (and the taxpayer) to the prescription manufacturing, distribution or dispensing industries. Shortages are a major indication of this trend, and they are likely to get worse unless there are major cash injections into the supply chain and Pharmacy. I would imagine that if we went to the Pharmacy show again in 15 years time we would struggle to find any organisation talking about prescription medicine at all as patients may be swapping to over-the-counter medicines such as cannabis oils because they cannot get appointments or prescriptions. #npa #nationalpharmacyassociation #UKPharmacy

**Initial October 2024 NCSO Concessions Report now LIVE** The first October 2024 Concession list (which shows which products are in short supply) is now available, and has been loaded into WaveData Live. All Users can access this report via the 'Reimbursement Prices' option on our main menu. We expect to see further Concessions as the month progresses and will update accordingly. For more UK Pharma Pricing news and insights visit www.wavedata.co.uk. #UKPharmaPricing #UKPharma #drugshortages

Check out the latest UK Price Watch article in the Generics Bulletin for analysis and insight on September’s product launches, the biggest risers, the biggest fallers and the fastest movers…. with market data provided by WaveData.   Dave Wallace, editor at Generics Bulletin, comments ‘September saw the extreme price rises of the last few months subside in the UK, albeit still seeing a handful of treble-digit percentage average increases for products like Telmisartan’.   Full article: https://lnkd.in/eqx_2d4b   More about WaveData: www.wavedata.co.uk   #pharmaindustry #pharmapricing #genericmedicines

We had a very interesting day at The Pharmacy Show yesterday. It was great to see so many familiar faces, and to meet some new contacts. If we missed you, but you would like to have a chat about how we can help your business better understand the dynamics of market pricing click below to book a call and a demo. https://lnkd.in/e9WszxzR #ukpharma #pharmapricing #pharmacyshow

Our managing director, Charles Joynson, will be at the pharmacy show at the NEC this Monday 14th October. Please make contact if you’d like to talk to him.

WaveData's Head of Data, Natalie Fancourt, alerted us to the huge price spikes on Apixaban 5mg 56. Charles Joynson, WaveData MD, decided to investigate the longer term view of both the Generic and Brand. The 5mg 56 pack is the most commonly used of the six packs of Apixaban available.   The first graph shows the long-term average price history, and a number of things need to be pointed out. There was a drop in the Eliquis PI and UK pack prices in 2016. This was due to a drop in the Drug Tariff and the branded product reimbursement price from £61.50 to £53.20 in April 2016, shown on the second graph. There was a slight overshoot when both PI and UK packs dropped to below £50.00, but they soon recovered to a competitive stability point of about £53.00 and stayed more or less at this level until generics appeared on the scene in May 2022. For a brief period of four months prices actually rose while the market was dominated by one generic manufacturer, after which others came into the market and prices fell rapidly from the £53.00 level down as low as £1.46 by June 2024. Noticeably both the UK and PI packs of Eliquis Tabs also fell, but nothing like as far as the generic. The PI fell to a low of £41.77 in June 2024, and the UK pack to £31.58 in May 2024. Both have since seen price rises. The generic product’s price drop was so rapid that prices fell below the level at which manufacturers could sustainably make a profit (probably about £2.00 in this case). This trigger point is the price at which manufacturers withdraw, triggering price rises, concessions and shortages. Consequently in August 2024 prices started rising again, reaching an average of £17.02 in September 2024. Concessions were announced by the department of Health and Social Care (DHSC) in July and August but not in September. The first indications of October pricing are between £7.25 and £13.89, which suggests that the price may have reached its peak. We’ll see if this is true in the coming weeks. #ukdrugshortages #genericdrugs #ukpharmapricing

The Top Ten Generic searches on the WaveData Live system are an interesting indicator of the focus areas for key players in the UK Pharma sector. Here's the countdown for August 2024........ You can see the Top Ten Brand searches, alongside other industry insights in the latest WaveData Bulletin. www.wavedata.co.uk/kb #pharmapricing #pharmatopten #wavedatabulletin

**FINAL September 2024 NCSO Concessions Report now LIVE** The final September 2024 Concession list (which shows which products are in short supply) is now available, and has been loaded into WaveData Live. All users can access this report via the 'Reimbursement Prices' option on our main menu. For more UK Pharma Pricing news and insights visit www.wavedata.co.uk. #UKPharmaPricing #UKPharma #drugshortages

The Top Ten Branded searches on the WaveData Live system are an interesting indicator of the focus areas for key players in the UK Pharma sector. Here's the countdown for September 2024........ You can see the Top Ten Generic searches, alongside other industry insights in the latest WaveData Bulletin. www.wavedata.co.uk/kb #pharmapricing #pharmatopten #wavedatabulletin

Great work by our Data Team last month - over 130,000 market prices were added to the WaveData Systems in September 2024, with the addition of 190 new products. If you are interested in the price of branded and generic medication, medical devices or nutritionals, in UK Primary Care you will not find a more comprehensive source of data anywhere. You can find out more at www.wavedata.co.uk. Well done Natalie Fancourt, Elizabeth Frisby, Debbie Betteley, Siria Norfolk, Jackie Moss and the whole team.